c-Met/HGFR
Les inhibiteurs de c-Met/HGFR ciblent le Récepteur du Facteur de Croissance des Hépatocytes (c-Met), une tyrosine kinase impliquée dans des processus cellulaires tels que la croissance, la motilité et la morphogenèse. La signalisation de c-Met est impliquée dans la progression du cancer, la métastase et la résistance aux thérapies. Inhiber c-Met peut perturber la croissance et la propagation des tumeurs, faisant de ces inhibiteurs des outils précieux dans la recherche sur le cancer. Chez CymitQuimica, nous proposons des inhibiteurs de c-Met/HGFR pour soutenir vos recherches en oncologie, métastase et thérapies ciblées contre le cancer.
147 produits trouvés pour "c-Met/HGFR".
Filtrer par
Pourcentage de pureté
0
100
|
0
|
50
|
90
|
95
|
100
- Tri par prix ascendant
- Tri par prix descendant
- Puretés inférieures
- Puretés supérieures
- Livraison estimée la plus rapide
Pamufetinib
CAS :Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase.Formule :C27H23FN4O4SDegré de pureté :99.39%Couleur et forme :White SolidMasse moléculaire :518.559Emibetuzumab
CAS :Emibetuzumab: potent humanized MET antibody, antitumor, inhibits HGF/MET pathways, for advanced prostate cancer research.Degré de pureté :96.5% (SDS-PAGE); 98.8% (SEC-HPLC) - 98.3% (SDS-PAGE); 98.9% (SEC-HPLC)Couleur et forme :Transparent LiquidMasse moléculaire :143.74 kDa (Predicted)SU 5616
CAS :SU 5616 (WAY-608241) regulates abnormal cell proliferation and modulates tyrosine kinase signaling.Formule :C13H8ClNOSDegré de pureté :98.84%Couleur et forme :SolidMasse moléculaire :261.727Onartuzumab
CAS :Onartuzumab (MetMAb) is a humanized monoclonal antibody targeting c-MET, with antitumor effects by blocking HGF and signal transduction.Degré de pureté :97.3%Couleur et forme :Transparent LiquidMasse moléculaire :146.99 kDa (Predicted)c-Met inhibitor 1
CAS :c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.Formule :C17H14N8SDegré de pureté :98.77%Couleur et forme :SolidMasse moléculaire :362.412CSF1R-IN-2
CAS :CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).Formule :C20H20FN7O2Degré de pureté :99.29%Couleur et forme :SolidMasse moléculaire :409.4169JNJ-38877618
CAS :JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).Formule :C20H12F2N6Degré de pureté :98.84% - 99.74%Couleur et forme :Yellow SolidMasse moléculaire :374.3463Bozitinib
CAS :Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.Formule :C20H15F3N8Degré de pureté :99.16%Couleur et forme :SolidMasse moléculaire :424.3819Rilotumumab
CAS :Rilotumumab (AMG 102) is an HGF-targeting antibody, inhibits HGF/MET signaling, and is used for CRPC and gastric cancer research.Degré de pureté :SDS-PAGE:95% SEC-HPLC:97.51%Couleur et forme :Transparent LiquidMasse moléculaire :145.2 kDa (Predicted)PROTAC c-Met degrader-2
CAS :PROTACc-Met degrader-2 (PROTAC2) is a c-Met degrader developed using PROTAC technology, with a DC50 value of 50 nM.Formule :C51H50F2N6O13Couleur et forme :SolidMasse moléculaire :992.97c-Met ligand-Linker Conjugate 1
c-Met ligand-Linker Conjugate 1 is a Target Protein Ligand-Linker Conjugate that consists of a c-Met ligand and a PROTAC linker, capable of recruiting E3 ligase. This compound is used in the synthesis of PROTACc-Met degrader-5.Couleur et forme :Odour SolidFosgonimeton acetate
Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).Formule :C29H49N4O10PDegré de pureté :98.01%Couleur et forme :SolidMasse moléculaire :644.69c-Met-IN-23
c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent.Formule :C16H13N7OMasse moléculaire :319.11816Zurletrectinib
CAS :Zurletrectinib is a tyrosine kinase inhibitor with potential as an antineoplastic agent.Formule :C19H19F2N7O2Couleur et forme :SolidMasse moléculaire :415.4Caveolin-1 (82-101) amide (human, mouse, rat)
CAS :Caveolin-1 (82-101) amide (human, mouse, rat), also known as Caveolin-1 scaffolding domain peptide, mitigates aging-related detrimental alterations in variousFormule :C124H170N28O29Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :2516.85PROTAC c-Met Degrader-4
CAS :PROTAC c-Met Degrader-4 is an orally active PROTAC c-MET degrader with DC50 <0.5 nM that inhibits cancer cell growth and xenograft tumors.Formule :C47H44N10O7Degré de pureté :97.19%Masse moléculaire :860.93PROTAC c-Met degrader-3
PROTACc-Met degrader-3 (Compound 22b) is a c-Met PROTAC degrader. It facilitates the ubiquitination and degradation of c-Met, with a DC50 of 0.59 nM in EBC-1 cells. PROTACc-Met degrader-3 is applicable in lung cancer research.Formule :C51H54N10O7Couleur et forme :SolidMasse moléculaire :919.037LMTK3-IN-1
CAS :Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.Formule :C18H11F3N4ODegré de pureté :99.58%Couleur et forme :Yellow SolidMasse moléculaire :356.3Norleual
CAS :Angiotensin IV analog, potent HGF/c-MET inhibitor (IC50=3 pM), halts MDCK cell growth and invasion, AT4 antagonist, impairs LTP, antiangiogenic.Formule :C41H58N8O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :774.95PF-04217903 phenolsulfonate
CAS :PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).Formule :C25H22N8O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :546.56
